Suchergebnisse - "Goldman, Jonathan W"

PubPharm (136)

1

A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors : phase 1 trial interim results

enthalten in: Nature medicine | 2024

von Rappaport, A. | Kyi, C. | Lane, M. | +35

2

Summary of Research : Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

enthalten in: Targeted oncology | 2024

von Tsuboi, M. | Herbst, R. | John, T. | +18

3

Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer : A Nonrandomized Controlled Trial

enthalten in: JAMA oncology | 2024

von Wu, T. | Luterstein, E. | Neilsen, B. | +10

CommentOn: JAMA Oncol. 2024 Mar 1;10(3):360-361. - PMID 38206616

4

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

enthalten in: Targeted oncology | 2024

von Tsuboi, M. | Herbst, R. | John, T. | +18

5

Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden

enthalten in: Psychosomatic medicine | 2024

von Williamson, T. | Garon, E. | Irwin, M. | +3

6

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN) : Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Paz-Ares, L. | Garassino, M. | Chen, Y. | +19

CommentIn: Clin Cancer Res. 2024 Feb 16;30(4):652-654. - PMID 38085269

7

A plain language summary of the PHAROS study : the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

enthalten in: Future oncology (London, England) | 2024

von Riely, G. | Smit, E. | Ahn, M. | +22

8

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

enthalten in: The New England journal of medicine | 2023

von Zhou, C. | Tang, K. | Cho, B. | +126

CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF9. - PMID 37878779

9

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC : Updated Analysis From the Phase 3 ADAURA Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von John, T. | Grohé, C. | Goldman, J. | +17

10

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Rotow, J. | Patel, J. | Hanley, M. | +15

CommentIn: Clin Cancer Res. 2023 Aug 15;29(16):2951-2953. - PMID 37314773

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[14]